CureVac CFO Sees ‘No Strings Attached’ to German Investment

The transcript discusses the importance of liquidity for biotech companies, highlighting a German Government equity investment in a biotech firm. It addresses the challenges of developing messenger RNA vaccines, including regulatory hurdles and the need for clinical trials. The conversation also touches on funding needs and speculations about a potential NASDAQ IPO, emphasizing the importance of capital access for biotech companies.

What is the company's strategy for developing a more potent vaccine?

How does the company plan to utilize the investment from the German Government?

What are the implications of a potential NASDAQ IPO for the company?